- Home
- IMUX vs PHH Comparison
IMUX vs PHH Comparison
Compare IMUX & PHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- PHH
- Stock Information
- Founded
- IMUX 2016
- PHH 2016
- Country
- IMUX United States
- PHH China
- Employees
- IMUX N/A
- PHH N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- PHH Package Goods/Cosmetics
- Sector
- IMUX Health Care
- PHH Consumer Discretionary
- Exchange
- IMUX Nasdaq
- PHH Nasdaq
- Market Cap
- IMUX 100.0M
- PHH 115.3M
- IPO Year
- IMUX N/A
- PHH 2024
- Fundamental
- Price
- IMUX $0.95
- PHH $5.71
- Analyst Decision
- IMUX Strong Buy
- PHH
- Analyst Count
- IMUX 6
- PHH 0
- Target Price
- IMUX $12.67
- PHH N/A
- AVG Volume (30 Days)
- IMUX 991.0K
- PHH 271.6K
- Earning Date
- IMUX 02-20-2025
- PHH 01-01-0001
- Dividend Yield
- IMUX N/A
- PHH N/A
- EPS Growth
- IMUX N/A
- PHH N/A
- EPS
- IMUX N/A
- PHH 0.02
- Revenue
- IMUX N/A
- PHH $1,940,443.00
- Revenue This Year
- IMUX N/A
- PHH N/A
- Revenue Next Year
- IMUX N/A
- PHH N/A
- P/E Ratio
- IMUX N/A
- PHH $372.94
- Revenue Growth
- IMUX N/A
- PHH 108.42
- 52 Week Low
- IMUX $0.95
- PHH $3.70
- 52 Week High
- IMUX $2.11
- PHH $6.90
- Technical
- Relative Strength Index (RSI)
- IMUX 36.31
- PHH N/A
- Support Level
- IMUX $0.99
- PHH N/A
- Resistance Level
- IMUX $1.05
- PHH N/A
- Average True Range (ATR)
- IMUX 0.07
- PHH 0.00
- MACD
- IMUX -0.00
- PHH 0.00
- Stochastic Oscillator
- IMUX 1.50
- PHH 0.00
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.